Tyrosine kinase inhibitors like pazopanib, cabozantinib, or vandetanib act by inhibiting the VEGF signaling cascade and have an anti-angiogenetic effect, preventing tumor growth and providing a promising treatment option to otherwise untreatable cancers. The gene discussed is VEGFA; the disease is neoplasm.